GenSight Biologics SA (FR:SIGHT)
:SIGHT
Total Valuation
GenSight Biologics SA has a market cap or net worth of €20.72M. The enterprise value is €25.68M.
Market Cap€20.72M
Enterprise Value€25.68M
Share Statistics
GenSight Biologics SA has 235,044,330 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding235,044,330
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
GenSight Biologics SA’s return on equity (ROE) is 0.48 and return on invested capital (ROIC) is 1518.16%.
Return on Equity (ROE)0.48
Return on Assets (ROA)-1.46
Return on Invested Capital (ROIC)1518.16%
Return on Capital Employed (ROCE)2.65
Revenue Per Employee62.50
Profits Per Employee-752.25K
Employee Count16
Asset Turnover<0.01
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of GenSight Biologics SA is ―. GenSight Biologics SA’s PEG ratio is 0.03.
PE Ratio―
PS Ratio15482.52
PB Ratio-0.62
Price to Fair Value-0.62
Price to FCF0.00
Price to Operating Cash Flow-1.85
PEG Ratio0.03
Income Statement
In the last 12 months, GenSight Biologics SA had revenue of 1.00K and earned -12.04M in profits. Earnings per share was -0.08.
Revenue1.00K
Gross Profit0.00
Operating Income-11.71M
Pretax Income-12.04M
Net Income-12.04M
EBITDA-11.24M
Earnings Per Share (EPS)-0.08
Cash Flow
In the last 12 months, operating cash flow was -8.95M and capital expenditures 6.49M, giving a free cash flow of -2.46M billion.
Operating Cash Flow-8.95M
Free Cash Flow-2.46M
Free Cash Flow per Share-0.01
Dividends & Yields
GenSight Biologics SA pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.64
52-Week Price Change-60.54%
50-Day Moving Average0.08
200-Day Moving Average0.12
Relative Strength Index (RSI)50.54
Average Volume (3m)616.46K
Important Dates
GenSight Biologics SA upcoming earnings date is Jul 23, 2026, TBA (Confirmed).
Last Earnings DateMar 27, 2026
Next Earnings DateJul 23, 2026
Ex-Dividend Date―
Financial Position
GenSight Biologics SA as a current ratio of 0.39, with Debt / Equity ratio of -51.57%
Current Ratio0.39
Quick Ratio0.39
Debt to Market Cap0.83
Net Debt to EBITDA-0.93
Interest Coverage Ratio-11.86
Taxes
In the past 12 months, GenSight Biologics SA has paid 5.00K in taxes.
Income Tax5.00K
Effective Tax Rate>-0.01
Enterprise Valuation
GenSight Biologics SA EV to EBITDA ratio is -2.31, with an EV/FCF ratio of 0.00.
EV to Sales25.93K
EV to EBITDA-2.31
EV to Free Cash Flow0.00
EV to Operating Cash Flow-2.83
Balance Sheet
GenSight Biologics SA has €2.42M in cash and marketable securities with €12.86M in debt, giving a net cash position of -€10.45M billion.
Cash & Marketable Securities€2.42M
Total Debt€12.86M
Net Cash-€10.45M
Net Cash Per Share-€0.04
Tangible Book Value Per Share-€0.17
Margins
Gross margin is 4800.00%, with operating margin of -1170500.00%, and net profit margin of -1203600.00%.
Gross Margin4800.00%
Operating Margin-1170500.00%
Pretax Margin-1204100.00%
Net Profit Margin-1203600.00%
EBITDA Margin-1124000.00%
EBIT Margin-1170500.00%
Analyst Forecast
The average price target for GenSight Biologics SA is €0.40, which is 11.43% higher than the current price. The consensus rating is Hold
Price Target€0.40
Price Target Upside344.44% Upside
Analyst ConsensusHold
Analyst Count1
Revenue Growth Forecast-92.35%
EPS Growth Forecast63.25%